Moderna says FDA will consider new flu shot after resolving public dispute

The FDA will now consider Moderna's mRNA flu vaccine application after a dispute over clinical trial design. Moderna agreed to seek full approval for adults 50-64 and accelerated approval for those 65 and older, with a post-market study. This resolution follows heightened scrutiny of mRNA vaccines under Health Secretary Robert F. Kennedy Jr.